CAMBRIDGE, Mass.--(BUSINESS WIRE)--BioBehavioral Diagnostics Company (BioBDx), recently appointed Calvin R. Sumner, M.D., as chief medical officer and senior vice president of clinical development. Dr. Sumner brings extensive experience in clinical product development for the treatment of psychiatric and behavioral conditions affecting children, adolescents, and adults. His expertise will be critical in supporting BioBDx as it pursues new indications and prepares for the commercial launch of MMAT/ADHD™ System, the first FDA-cleared diagnostic system to provide objective measures for the symptoms of ADHD.
